Respiri ( ) - 株価, ニュースと分析ASX:RSH

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

RSH 株式概要

レスピリ・リミテッドはeヘルスSaaS企業で、オーストラリアで医療機器の研究、開発、商品化を行う。

RSH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

報酬

リスク分析

収益が 100 万ドル未満 ( A$790K )

過去1年間で株主の希薄化が進んだ

意味のある時価総額がありません ( A$29M )

過去3か月間の株価の変動

Respiri Limited 競合他社

Atomo Diagnostics

ASX:AT1

AU$19.2m

Resonance Health

ASX:RHT

AU$26.8m

Universal Biosensors

ASX:UBI

AU$43.2m

CleanSpace Holdings

ASX:CSX

AU$18.9m

価格と性能

Summary of all time highs, changes and price drops for Respiri
Historical stock prices
Current Share Price	AU$0.027
52 Week High	AU$0.043
52 Week Low	AU$0.021
Beta	0.093
1 Month Change	-27.03%
3 Month Change	-6.90%
1 Year Change	-28.95%
3 Year Change	-61.43%
5 Year Change	-70.00%
Change since IPO	-97.68%

Recent updates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

株主還元

	RSH	AU Medical Equipment	AU 市場
7D	-3.6%	-1.0%	-2.0%
1Y	-28.9%	20.1%	6.1%

業界別リターン: RSH過去 1 年間で20 % の収益を上げたAustralian Medical Equipment業界を下回りました。

リターン対市場: RSHは、過去 1 年間で8.2 % のリターンを上げたAustralian市場を下回りました。

価格変動

Is RSH's price volatile compared to industry and market?
RSH volatility
RSH Average Weekly Movement	15.8%
Medical Equipment Industry Average Movement	9.5%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	16.1%
10% least volatile stocks in AU Market	3.2%

安定した株価: RSHの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: RSHの weekly volatility ( 16% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	n/a	Marjan Mikel	respiri.co

レスピリ（Respiri Limited）はeヘルスSaaS企業で、オーストラリアで医療機器の研究、開発、商業化を行う。モバイルヘルスアプリケーションの開発、製造、販売を行っている。製品には、子供の喘鳴を検出する電子喘鳴検出ツール「wheezo」、respiriモバイルアプリケーション、respiri健康ポータルなどがある。旧社名はiSonea Limitedで、2015年12月に社名をRespiri Limitedに変更した。本社はオーストラリアのメルボルン。

Respiri Limited 基礎のまとめ

Respiri の収益と売上を時価総額と比較するとどうか。
RSH 基礎統計学
時価総額	AU$28.62m
収益（TTM）	-AU$6.39m
売上高(TTM)	AU$789.74k

36.2x

P/Sレシオ

-4.5x

PER（株価収益率

RSH は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
RSH 損益計算書（TTM）
収益	AU$789.74k
売上原価	AU$23.74k
売上総利益	AU$766.00k
その他の費用	AU$7.15m
収益	-AU$6.39m

直近の収益報告

Dec 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.006
グロス・マージン	96.99%
純利益率	-808.52%
有利子負債／自己資本比率	0%

RSH の長期的なパフォーマンスは？

過去の実績と比較を見る

RSH 株式概要

報酬

リスク分析

Respiri Limited 競合他社

ASX:AT1

AU$19.2m

ASX:RHT

AU$26.8m

ASX:UBI

AU$43.2m

ASX:CSX

AU$18.9m

価格と性能

最新ニュース

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Respiri Limited Announces Executive Changes

New major risk - Share price stability

Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million.

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Less than half of directors are independent

Recent updates

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Respiri Limited Announces Executive Changes

New major risk - Share price stability

Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million.

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.009 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

New minor risk - Share price stability

Respiri Limited Appoints Brian Leedman as Non-Executive Director

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Respiri Limited Announces Arkansas Heart Hospital Commences Patients on Wheezo RPM

Respiri Limited Announces Minnesota Lung Center Wheezo Rpm Pilot Program Patient Selection Has Been Finalised and Patient Onboarding Has Successfully Commence

No independent directors

Respiri Announces First Patients Enrolled into Wheezo® Remote Patient Monitoring Programs, Further Validating USA Business Model

Respiri Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings released

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Respiri Limited Announces Executive Changes

Respiri Limited Announces New £2 Million NIHR-Funded UK Paediatric Asthma Clinical Trial with wheezo

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Respiri Limited Announces Resignation of Director of Dr. Thomas Duthy

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Full year 2021 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in FY 2020)

Respiri Limited Announces Wheezo Registered and Approved for Sale in the UK Market

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Insider recently bought AU$95k worth of stock

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Respiri Limited Announces New Partnership with Pharmacy 4 Less Banner Group

Respiri Limited Holds Media Events to Mark the Launch of Wheezo

Respiri Limited, Annual General Meeting, Dec 16, 2020

Respiri Limited Files Additional Patent Application

Respiri Limited Announces A Partnership with Entech Electronics for the Global Supply of the Ground Breaking Wheezo

Respiri Limited to Report Fiscal Year 2020 Results on Aug 25, 2020

Respiri Limited announced that it expects to receive AUD 0.09 million in funding

株主還元

価格変動

会社概要

Respiri Limited 基礎のまとめ

36.2x

-4.5x

収益と収入